California
Duarte; City of Hope
RTOG 0522: A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) Followed by Surgery for Selected Patients for Stage III and IV Head and Neck Carcinomas
Duarte; City of Hope
A Phase I Trial of Re-Irradiation by Helical Tomotherapy in Combination with Oxaliplatin in Patients with Previously Irradiated Recurrent Head and Neck Cancer
Illinois
Chicago; University of Chicago Medical Center
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
Chicago; University of Chicago
Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients with Head and Neck Cancer
Chicago; University of Chicago
A Study of TNFerade ™ with Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients with Head and Neck Cancer
New York
Albany; New York Oncology
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
Albany; New York Oncology Hematology
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
New Hyde Park; Biomedical Research Alliance of New York
People with Head and Neck Squamous Cell Carcinoma are asked to participate in a research study being conducted by Long Island Jewish Medical Center.
New York; Mount Sinai Medical Center
A Phase III, Multicenter, Randomized,Double-Blind,Placebo-Controlled Study to Assess Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region
Staten Island; Biomedical Research Alliance of New York
Raising the Xerostomia Threshold by Pretreatment with Amifostine
Staten Island; Biomedical Research Alliance of New York
Advanced Squamous Cell Cancers of the Head and Neck
Texas
Dallas; Mary Crowley Cancer Research Center
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Carcinoma Of The Head And Neck
Tyler; Tyler Cancer Center
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
International
Alcorcon, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
Barcelona, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
Burgos, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
Córdoba, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
Granada, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
Guadalajara, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
Jaen, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
Lugo, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
Madrid, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
Murcia, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
Orense, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
Palma de Mallorca, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
Salamanca, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
San Sebastian, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
Santander, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
Sevilla, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
Toledo, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
Valencia, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
Zamora, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
Zaragoza, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
